ArticleClinical and experimental reproductive medicine2021
The role of gonadotropin-releasing hormone agonists in female fertility preservation.
Article in Clinical and experimental reproductive medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Fertility in breast cancer survivorship: a scoping review.Journal of cancer survivorship : research and practice · 2026Review
- Review
- Uterine transposition for fertility preservation prior to pelvic irradiation: an initial Egyptian case series.Journal of the Egyptian National Cancer Institute · 2026Article
- Research progress on multi-mechanism analysis and protection strategies of ovarian aging and fertility decline.Journal of ovarian research · 2026Review
- Chemotherapy-Induced Infertility: Mechanisms, Risk Factors, and Fertility Preservation Strategies in Cancer Patients.JBRA assisted reproduction · 2026Review
- Long-term outcomes of fertility preservation counseling in women of reproductive age prior to gonadotoxic therapy.Journal of ovarian research · 2026Article
- Investigating the effects of rosmarinic acid on ovarian tissue, inflammatory markers, and sex hormones in polycystic ovary syndrome rats.Physiological reports · 2025Article
- Anti-Mullerian Hormone and conception timing as predictors of live births in cancer patients using fertility preservation: a systematic review.Frontiers in oncology · 2025Review
- The Effects of L-Tartaric Acid on Ovarian Histostereological and Serum Hormonal Analysis in an Animal Model of Polycystic Ovary Syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Gonadotropin-Releasing Hormone Receptor (GnRHR) and Hypogonadotropic Hypogonadism.International journal of molecular sciences · 2023Review
- Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.Neuro-oncology · 2023Article
- Classical music restored fertility status in rat model of premature ovarian failure.BMC complementary medicine and therapies · 2022Article
- Fertility after Cancer: Risks and Successes.Cancers · 2022Review
- Artificial Ovary for Young Female Breast Cancer Patients.Frontiers in medicine · 2022Review
- A Warning Call for Fertility Preservation Methods for Women Undergoing Gonadotoxic Cancer Treatment.Medicina (Kaunas, Lithuania) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Advances in anticancer treatments have resulted in increasing survival rates among cancer patients. Accordingly, the quality of life after treatment, particularly the preservation of fertility, has gradually emerged as an essential consideration. Cryopreservation of embryos or unfertilized oocytes has been considered as the standard method of fertility preservation among young women facing gonadotoxic chemotherapy. Other methods, including ovarian suppression and ovarian tissue cryopreservation, have been considered experimental. Recent large-scale randomized controlled trials have demonstrated that temporary ovarian suppression using gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy is beneficial for preventing chemotherapy-induced premature ovarian insufficiency in breast cancer patients. It should also be emphasized that GnRHa use during chemotherapy does not replace established fertility preservation methods. All young women facing gonadotoxic chemotherapy should be counseled about and offered various options for fertility preservation, including both GnRHa use and cryopreservation of embryos, oocytes, and/or ovarian tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.